Jain Global LLC Acquires Shares of 132,836 Sanofi $SNY

Key Points

• Jain Global LLC opened a new stake in Sanofi during Q3, purchasing 132,836 shares worth about $6.27 million.
• Analyst sentiment has cooled with several recent downgrades; Sanofi's consensus rating is Hold and the average price target is $62.67.
• Sanofi shares were trading around $43.98 (one‑year low $43.34, high $59.17) with a market cap of roughly $107.3 billion and a P/E of about 12.2.

Jain Global LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 132,836 shares of the company's stock, valued at approximately $6,270,000.

Several other hedge funds and other institutional investors also recently modified their holdings of SNY. Waterfront Wealth Inc. lifted its position in shares of Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company's stock worth $2,463,000 after buying an additional 214 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in Sanofi by 2.3% during the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company's stock worth $468,000 after acquiring an additional 226 shares in the last quarter. HM Payson & Co. raised its stake in Sanofi by 3.4% during the third quarter. HM Payson & Co. now owns 7,248 shares of the company's stock worth $342,000 after acquiring an additional 235 shares in the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in shares of Sanofi by 4.7% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company's stock worth $252,000 after acquiring an additional 238 shares during the last quarter. Finally, CreativeOne Wealth LLC lifted its holdings in shares of Sanofi by 2.8% in the second quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company's stock worth $434,000 after acquiring an additional 241 shares during the last quarter. Institutional investors own 14.03% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SNY. Guggenheim lowered shares of Sanofi from a "buy" rating to a "neutral" rating in a report on Tuesday, December 9th. Bank of America lowered shares of Sanofi from a "buy" rating to a "neutral" rating in a research report on Thursday, February 12th. Wall Street Zen cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. UBS Group reiterated a "neutral" rating on shares of Sanofi in a report on Friday, January 16th. Finally, TD Cowen reiterated a "hold" rating on shares of Sanofi in a research note on Tuesday, December 30th. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of "Hold" and an average price target of $62.67.

Sanofi Stock Up 0.9%

Shares of NASDAQ SNY opened at $43.98 on Tuesday. The company has a 50 day simple moving average of $46.78 and a 200 day simple moving average of $48.17. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a 1 year low of $43.34 and a 1 year high of $59.17. The firm has a market cap of $107.27 billion, a PE ratio of 12.22, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

Sanofi Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.